Mankind Pharma

Mankind Pharma, Bajaj Housing, Ola Electric, 40 others to exit IPO lock-in

Here is the complete list of stocks exiting their IPO lock-in period between October 8, 2024, and December 31, 2024

Stocks To Watch: SBI, Mankind, Adani Enterprises, Dr. Reddy's, Zydus Life

Stocks to watch: SBI plans to open 600 new branches this fiscal year to expand its reach in emerging residential areas, said its chairman and managing director CS Setty.

CCI approves Mankind Pharma's purchase of Bharat Serums for $1.6 bn

Mankind Pharma, which has brands including Manforce condoms and Prega News pregnancy tests, signed an agreement to acquire Bharat Serums

Mankind Pharma board approves fundraising plan of up to Rs 10,000 cr

Mankind Pharma on Monday said it will raise up to Rs 10,000 crore via issuance of non-convertible debentures and commercial papers. The company said its board has approved to raise up to Rs 5,000 crore via non-convertible debentures in 3-4 distinct series with maturities of up to 48 months. The board's fundraising committee also approved to raise up to Rs 5,000 crore via listed and rated commercial papers, having face value as may be decided in accordance with applicable law, in one or more tranches or series, the drug maker said in a regulatory filing. The company, however, did not disclose how it aims to utilise the raised capital. In July this year, Mankind had announced the acquisition of Bharat Serums and Vaccines from Advent International for around Rs 13,630 crore. The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and consumer healthcare products. Shares of the company on Monday ended 2.68 per cent down at Rs .

Mankind Pharma up 4% as board approves raising Rs 10,000-cr via NCDs, CPs

Mankind Pharma approved raising Rs 10,000 crore via the issuance of Non-Convertible Debentures (NCD) and Commercial Papers (CP)

Mankind Pharma to raise funds up to Rs 10k crore via debt instruments

The board announced the issuance of corporate guarantees for four of its subsidiaries, namely Mankind Agritech, Appian Properties, Copmed Pharmaceuticals, and Lifestar Pharma.

Mankind up 7% ahead of board meet for fund raising; m-cap tops Rs 1 trn

The board is to consider and approve the raising of funds by way of issue of non-convertible debentures, commercial papers, other debt securities or any other security or any combination thereof.

Mankind Pharma shares gain after OTC biz transfer to subsidiary; details

Mankind Pharma share price surged after the company on Tuesday completed a business transfer agreement (BTA) to shift its over-the-counter (OTC) business to its wholly owned subsidiary

Mankind up 3% after reports say co looking to raise Rs 9k cr for BSV deal

Mankind Pharma is likely to raise Rs 9,000 crore through NCDs to acquire Bharat Serums and Vaccines

Mankind Pharma plans Rs 9,000 crore raise for Bharat Serums acquisition

The move will position Mankind as a leader in the gynaecology-fertility segment, with an anticipated market share of around 20%, surpassing Emcure

Acquisition of BSV to aid future growth of Mankind Pharma: V-C Juneja

The acquisition of Bharat Serums and Vaccines would add a lot of value, aiding future growth of Mankind Pharma, according to Vice Chairman and Managing Director Rajeev Juneja. On July 25, Mankind had announced that it will fully acquire Bharat Serums and Vaccines (BSV) from Advent International for an enterprise value of around Rs 13,630 crore. "One thing should be very clear, this acquisition is not to really add some kind of revenue, but to add a lot of value, future growth, entry barrier, super specialty business in Mankind," Juneja said in an analyst call. Whatever the company is paying for BSV, it is very relevant as the company has "so much of value" with well established business, he said. The acquisition is in line with the company's strategy of buying high entry barrier businesses, he stated. The buyout will solidify Mankind's position with complementary drug portfolio and extensive reach to target rapidly growing highly under-penetrated markets, especially in fertility,

Mankind Pharma Q1 results: Profit up 9.9% at Rs 543 cr; revenue rises 12%

Mankind also announced a rise in its prescriber penetration to 83.2 per cent in Q1 FY25, from 82.7 per cent in the same quarter last financial year

BSV portfolio can touch Rs 5K cr in 3-4 yrs: Mankind Pharma's Rajeev Juneja

'We don't want to get into exports with generic or me-too products. We always wanted products with a high level of entry barriers and complexity'

Mankind Pharma to lead in Indian women's health market after BSV deal

Deal opens doors to overseas markets with low competition

Mankind Pharma acquires Bharat Serums and Vaccines for Rs 13,600 crore

More than 2,500 BSV employees will be joining Mankind

Mankind Pharma frontrunner to acquire Bharat Serums in $1.5 bn deal

Mankind Pharma rose as much as 1.2 per cent following Thursday's Bloomberg News report. The shares are up about 6.5 per cent this year and 10 per cent in the past 12 months

Mankind Pharma and EQT compete to acquire BSV Group for Rs 14,000 crore

Advent International, the private equity firm currently owning BSV, appointed JP Morgan and Jefferies to facilitate the sale of the biopharma firm

Mankind Pharma inks pact with Takeda to commercialise acidity drug in India

The agreement allows Mankind Pharma to launch the novel drug for treating Gastroesophageal Reflux Disease

Mankind Pharma rallies 5% after 3.7 mn shares change hands via block deal

Mankind Pharma, the domestic pharmaceutical major's stock price surged up to 5.27 per cent at Rs 2,215 per share on the BSE in Wednesday's intraday trade

Stocks to watch, July 10: Angel One, Emcure Pharma, Mankind Pharma, M&M

Stocks to watch on July 10: Emcure Pharmaceuticals' shares are scheduled to make their debut on the stock exchanges on Wednesday